世界の呼吸器抗ウィルス治療市場2020年ー2030年:薬剤分類別(ヌクレオシド類似体、ノイラミニダーゼ阻害剤、イオンチャネル遮断薬、融合タンパク質阻害剤)、疾患別、流通チャネル別

◆英語タイトル:Respiratory Antiviral Treatment Market (Drug Class: Nucleoside Analogs, Neuraminidase Inhibitors, Ion Channel Blockers, and Fusion Protein Inhibitors; Disease Type: Influenza, Bronchiolitis, Pneumonia, Upper Respiratory Tract Infections (URTIs), and Others; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030
◆商品コード:TMR21MC118
◆発行会社(リサーチ会社):Transparency Market Research
◆発行日:2020年10月1日
◆ページ数:204
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD5,795 ⇒換算¥666,425見積依頼/購入/質問フォーム
Site Licence(同一拠点内共有可)USD8,795 ⇒換算¥1,011,425見積依頼/購入/質問フォーム
Enterprisewide Licence(複数拠点内共有可)USD11,795 ⇒換算¥1,356,425見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTransparency Market Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Transparency Market Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Transparency Market Research社の本調査資料では、世界の呼吸器抗ウィルス治療市場を広く調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、市場展望、薬剤分類別(ヌクレオシド類似体、ノイラミニダーゼ阻害剤、イオンチャネル遮断薬、融合タンパク質阻害剤)分析、疾患別分析、流通チャネル別分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)分析、競争状況など、以下の構成でまとめております。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・市場展望
・呼吸器抗ウィルス治療の世界市場規模:薬剤分類別(ヌクレオシド類似体、ノイラミニダーゼ阻害剤、イオンチャネル遮断薬、融合タンパク質阻害剤)
・呼吸器抗ウィルス治療の世界市場規模:疾患別
・呼吸器抗ウィルス治療の世界市場規模:流通チャネル別
・呼吸器抗ウィルス治療の世界市場規模:地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)
・競争状況
【レポートの概要】

Respiratory Antiviral Treatment Market – Scope of the Report

TMR’s report on the global respiratory antiviral treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators for the market during the forecast period from 2020 to 2030. The report provides revenue of the global respiratory antiviral treatment market for the period 2018–2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) of the global respiratory antiviral treatment market from 2020 to 2030.

The report is prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the respiratory antiviral treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the respiratory antiviral treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global respiratory antiviral treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global respiratory antiviral treatment market.

The report delves into the competition landscape of the global respiratory antiviral treatment market. Key players operating in the global respiratory antiviral treatment market are identified and each one of these is profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global respiratory antiviral treatment market profiled in this report.

Key Questions Answered in Respiratory Antiviral Treatment Market Report

What is the sales/revenue generated by respiratory antiviral treatment across all regions during the forecast period?
What are the opportunities in the global respiratory antiviral treatment market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which drug class segment is expected to generate the highest revenue globally in 2030? Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Respiratory Antiviral Treatment Market – Research Objectives and Research Approach

The comprehensive report on the global respiratory antiviral treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global respiratory antiviral treatment market in terms of drug class, disease type, distribution channel, and region. Key segments under each criteria are studied at length, and the market share for each of these at the end of 2030 has also been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global respiratory antiviral treatment market.

【レポートの目次】

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Key Industry Developments
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunity
4.4. Global Respiratory Antiviral Treatment Market Forecast
4.5. Global Respiratory Antiviral Treatment Market Outlook
5. Market Outlook
5.1. Pipeline Analysis
5.2. Disease Prevalence Rate Globally with Key Countries
5.3. COVID-19 Impact Analysis
6. Global Respiratory Antiviral Treatment Market Analysis, by Drug Class
6.1. Introduction
6.2. Global Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class
6.3. Global Respiratory Antiviral Treatment Market Forecast, by Drug Class
6.3.1. Nucleoside Analogs
6.3.1.1. Ribavirin
6.3.1.2. Aciclovir
6.3.1.3. Others
6.3.2. Neuraminidase Inhibitors
6.3.2.1. Oseltamivir
6.3.2.2. Zanamivir
6.3.2.3. Others
6.3.3. Ion Channel Blockers
6.3.4. Fusion Protein Inhibitors
6.4. Global Respiratory Antiviral Treatment Market Analysis, by Drug Class
7. Global Respiratory Antiviral Treatment Market Analysis, by Disease Type
7.1. Introduction
7.2. Global Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type
7.3. Global Respiratory Antiviral Treatment Market Forecast, by Disease Type
7.3.1. Influenza
7.3.2. Bronchiolitis
7.3.3. Pneumonia
7.3.4. Upper Respiratory Tract Infections (URTIs)
7.3.5. Others (measles, etc.)
7.4. Global Respiratory Antiviral Treatment Market Analysis, by Disease Type
8. Global Respiratory Antiviral Treatment Market Analysis, by Distribution Channel
8.1. Introduction
8.2. Global Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
8.3. Global Respiratory Antiviral Treatment Market Forecast, by Distribution Channel
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Global Respiratory Antiviral Treatment Market Analysis, by Route of Administration
9. Global Respiratory Antiviral Treatment Market Analysis, by Region
9.1. Global Respiratory Antiviral Treatment Market Scenario, by Region/Country
9.2. Global Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Region
9.3. Global Respiratory Antiviral Treatment Market Forecast, by Region
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
10. North America Respiratory Antiviral Treatment Market Analysis
10.1. North America Respiratory Antiviral Treatment Market Overview
10.2. North America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country
10.3. North America Respiratory Antiviral Treatment Market Forecast, by Country
10.3.1. U.S.
10.3.2. Canada
10.4. North America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class
10.5. North America Respiratory Antiviral Treatment Market Forecast, by Drug Class
10.5.1. Nucleoside Analogs
10.5.1.1. Ribavirin
10.5.1.2. Aciclovir
10.5.1.3. Others
10.5.2. Neuraminidase Inhibitors
10.5.2.1. Oseltamivir
10.5.2.2. Zanamivir
10.5.2.3. Others
10.5.3. Ion Channel Blockers
10.5.4. Fusion Protein Inhibitors
10.6. North America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type
10.7. North America Respiratory Antiviral Treatment Market Forecast, by Disease Type
10.7.1. Influenza
10.7.2. Bronchiolitis
10.7.3. Pneumonia
10.7.4. Upper Respiratory Tract Infections (URTIs)
10.7.5. Others (measles, etc.)
10.8. North America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
10.9. North America Respiratory Antiviral Treatment Market Forecast, by Distribution Channel
10.9.1. Hospital Pharmacies
10.9.2. Retail Pharmacies
10.9.3. Online Pharmacies
11. Europe Respiratory Antiviral Treatment Market Analysis
11.1. Europe Respiratory Antiviral Treatment Market Overview
11.2. Europe Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.3. Europe Respiratory Antiviral Treatment Market Forecast, by Country/Sub-region
11.3.1. Germany
11.3.2. France
11.3.3. U.K.
11.3.4. Italy
11.3.5. Spain
11.3.6. Rest of Europe
11.4. Europe Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class
11.5. Europe Respiratory Antiviral Treatment Market Forecast, by Drug Class
11.5.1. Nucleoside Analogs
11.5.1.1. Ribavirin
11.5.1.2. Aciclovir
11.5.1.3. Others
11.5.2. Neuraminidase Inhibitors
11.5.2.1. Oseltamivir
11.5.2.2. Zanamivir
11.5.2.3. Others
11.5.3. Ion Channel Blockers
11.5.4. Fusion Protein Inhibitors
11.6. Europe Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type
11.7. Europe Respiratory Antiviral Treatment Market Forecast, by Disease Type
11.7.1. Influenza
11.7.2. Bronchiolitis
11.7.3. Pneumonia
11.7.4. Upper Respiratory Tract Infections (URTIs)
11.7.5. Others (measles, etc.)
11.8. Europe Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
11.9. Europe Respiratory Antiviral Treatment Market Forecast, by Distribution Channel
11.9.1. Hospital Pharmacies
11.9.2. Retail Pharmacies
11.9.3. Online Pharmacies
12. Asia Pacific Respiratory Antiviral Treatment Market Analysis
12.1. Asia Pacific Respiratory Antiviral Treatment Market Overview
12.2. Asia Pacific Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.3. Asia Pacific Respiratory Antiviral Treatment Market Forecast, by Country/Sub-region
12.3.1. Japan
12.3.2. China
12.3.3. India
12.3.4. Australia & New Zealand
12.3.5. Rest of Asia Pacific
12.4. Asia Pacific Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class
12.5. Asia Pacific Respiratory Antiviral Treatment Market Forecast, by Drug Class
12.5.1. Nucleoside Analogs
12.5.1.1. Ribavirin
12.5.1.2. Aciclovir
12.5.1.3. Others
12.5.2. Neuraminidase Inhibitors
12.5.2.1. Oseltamivir
12.5.2.2. Zanamivir
12.5.2.3. Others
12.5.3. Ion Channel Blockers
12.5.4. Fusion Protein Inhibitors
12.6. Asia Pacific Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type
12.7. Asia Pacific Respiratory Antiviral Treatment Market Forecast, by Disease Type
12.7.1. Influenza
12.7.2. Bronchiolitis
12.7.3. Pneumonia
12.7.4. Upper Respiratory Tract Infections (URTIs)
12.7.5. Others (measles, etc.)
12.8. Asia Pacific Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
12.9. Asia Pacific Respiratory Antiviral Treatment Market Forecast, by Distribution Channel
12.9.1. Hospital Pharmacies
12.9.2. Retail Pharmacies
12.9.3. Online Pharmacies
13. Latin America Respiratory Antiviral Treatment Market Analysis
13.1. Latin America Respiratory Antiviral Treatment Market Overview
13.2. Latin America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.3. Latin America Respiratory Antiviral Treatment Market Forecast, by Country/Sub-region
13.3.1. Brazil
13.3.2. Mexico
13.3.3. Rest of Latin America
13.4. Latin America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class
13.5. Latin America Respiratory Antiviral Treatment Market Forecast, by Drug Class
13.5.1. Nucleoside Analogs
13.5.1.1. Ribavirin
13.5.1.2. Aciclovir
13.5.1.3. Others
13.5.2. Neuraminidase Inhibitors
13.5.2.1. Oseltamivir
13.5.2.2. Zanamivir
13.5.2.3. Others
13.5.3. Ion Channel Blockers
13.5.4. Fusion Protein Inhibitors
13.6. Latin America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type
13.7. Latin America Respiratory Antiviral Treatment Market Forecast, by Disease Type
13.7.1. Influenza
13.7.2. Bronchiolitis
13.7.3. Pneumonia
13.7.4. Upper Respiratory Tract Infections (URTIs)
13.7.5. Others (measles, etc.)
13.8. Latin America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
13.9. Latin America Respiratory Antiviral Treatment Market Forecast, by Distribution Channel
13.9.1. Hospital Pharmacies
13.9.2. Retail Pharmacies
13.9.3. Online Pharmacies
14. Middle East & Africa Respiratory Antiviral Treatment Market Analysis
14.1. Middle East & Africa Respiratory Antiviral Treatment Market Overview
14.2. Middle East & Africa Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
14.3. Middle East & Africa Respiratory Antiviral Treatment Market Forecast, by Country/Sub-region
14.3.1. GCC Countries
14.3.2. South Africa
14.3.3. Rest of Middle East & Africa
14.4. Middle East & Africa Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class
14.5. Middle East & Africa Respiratory Antiviral Treatment Market Forecast, by Drug Class
14.5.1. Nucleoside Analogs
14.5.1.1. Ribavirin
14.5.1.2. Aciclovir
14.5.1.3. Others
14.5.2. Neuraminidase Inhibitors
14.5.2.1. Oseltamivir
14.5.2.2. Zanamivir
14.5.2.3. Others
14.5.3. Ion Channel Blockers
14.5.4. Fusion Protein Inhibitors
14.6. Middle East & Africa Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type
14.7. Middle East & Africa Respiratory Antiviral Treatment Market Forecast, by Disease Type
14.7.1. Influenza
14.7.2. Bronchiolitis
14.7.3. Pneumonia
14.7.4. Upper Respiratory Tract Infections (URTIs)
14.7.5. Others (measles, etc.)
14.8. Middle East & Africa Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
14.9. Middle East & Africa Respiratory Antiviral Treatment Market Forecast, by Distribution Channel
14.9.1. Hospital Pharmacies
14.9.2. Retail Pharmacies
14.9.3. Online Pharmacies
15. Competition Landscape
15.1. Competition Matrix
15.2. Company Profiles
15.2.1. F. Hoffmann-La Roche Ltd.
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Financial Overview
15.2.1.3. Product Portfolio
15.2.1.4. SWOT Analysis
15.2.1.5. Strategic Overview
15.2.2. Novartis AG
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Financial Overview
15.2.2.3. Product Portfolio
15.2.2.4. SWOT Analysis
15.2.2.5. Strategic Overview
15.2.3. Takeda Pharmaceutical Company Limited
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Financial Overview
15.2.3.3. Product Portfolio
15.2.3.4. SWOT Analysis
15.2.3.5. Strategic Overview
15.2.4. Pfizer, Inc.
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Product Portfolio
15.2.4.3. SWOT Analysis
15.2.4.4. Strategic Overview
15.2.5. Teva Pharmaceutical Industries Ltd.
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Financial Overview
15.2.5.3. Product Portfolio
15.2.5.4. SWOT Analysis
15.2.5.5. Strategic Overview
15.2.6. Sun Pharmaceutical Industries Ltd.
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Financial Overview
15.2.6.3. Product Portfolio
15.2.6.4. SWOT Analysis
15.2.6.5. Strategic Overview
15.2.7. GlaxoSmithKline plc
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Financial Overview
15.2.7.3. Product Portfolio
15.2.7.4. SWOT Analysis
15.2.7.5. Strategic Overview
15.2.8. Mylan, Inc.
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Financial Overview
15.2.8.3. Product Portfolio
15.2.8.4. SWOT Analysis
15.2.8.5. Strategic Overview
15.2.9. Merck & Co., Inc.
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Financial Overview
15.2.9.3. Product Portfolio
15.2.9.4. SWOT Analysis
15.2.9.5. Strategic Overview
15.2.10. AstraZeneca plc.
15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.10.2. Financial Overview
15.2.10.3. Product Portfolio
15.2.10.4. SWOT Analysis
15.2.10.5. Strategic Overview

List of Tables

Table 01: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 02: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030

Table 03: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030

Table 04: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 05: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 06: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Region, 2018–2030

Table 07: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country, 2018–2030

Table 08: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 09: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030

Table 10: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030

Table 11: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 12: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 13: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 14: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 15: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030

Table 16: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030

Table 17: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 18: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 19: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 20: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 21: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030

Table 22: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030

Table 23: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 24: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 25: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 26: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 27: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030

Table 28: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030

Table 29: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 30: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 31: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 32: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 33: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030

Table 34: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030

Table 35: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 36: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

List of Figures

Figure 01: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, 2018–2030

Figure 02: Global Respiratory Antiviral Treatment Market Value Share, by Drug Class, 2019

Figure 03: Global Respiratory Antiviral Treatment Market Value Share, by Distribution Channel, 2019

Figure 04: Global Respiratory Antiviral Treatment Market Value Share, by Disease Type, 2019

Figure 05: Global Respiratory Antiviral Treatment Market Value Share, by Region, 2019

Figure 06: Global Respiratory Antiviral Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030

Figure 07: Global Respiratory Antiviral Treatment Market Attractiveness, by Drug Class, 2020–2030

Figure 08: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Nucleoside Analogs, 2018–2030

Figure 09: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Neuraminidase Inhibitors, 2018–2030

Figure 10: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Ion Channel Blockers, 2018–2030

Figure 11: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Fusion Protein Inhibitors, 2018–2030

Figure 12: Global Respiratory Antiviral Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030

Figure 13: Global Respiratory Antiviral Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030

Figure 14: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Influenza, 2018–2030

Figure 15: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Bronchiolitis, 2018–2030

Figure 16: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Pneumonia, 2018–2030

Figure 17: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Upper Respiratory Tract Infections (URTIs), 2018–2030

Figure 18: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Others (Measles, etc.), 2018–2030

Figure 19: Global Respiratory Antiviral Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 20: Global Respiratory Antiviral Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 21: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Hospital Pharmacies, 2018–2030

Figure 22: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Retail Pharmacies, 2018–2030

Figure 23: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Online Pharmacies, 2018–2030

Figure 24: Global Respiratory Antiviral Treatment Market Value Share Analysis, by Region, 2019 and 2030

Figure 25: Global Respiratory Antiviral Treatment Market Attractiveness Analysis, by Region

Figure 26: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 27: North America Respiratory Antiviral Treatment Market Value Share (%), by Country, 2019 and 2030

Figure 28: North America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Country, 2020–2030

Figure 29: North America Respiratory Antiviral Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030

Figure 30: North America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Drug Class, 2020–2030

Figure 31: North America Respiratory Antiviral Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030

Figure 32: North America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030

Figure 33: North America Respiratory Antiviral Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 34: North America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 35: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 36: Europe Respiratory Antiviral Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 37: Europe Respiratory Antiviral Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 38: Europe Respiratory Antiviral Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030

Figure 39: Europe Respiratory Antiviral Treatment Market Attractiveness Analysis, by Drug Class, 2020–2030

Figure 40: Europe Respiratory Antiviral Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030

Figure 41: Europe Respiratory Antiviral Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030

Figure 42: Europe Respiratory Antiviral Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 43: Europe Respiratory Antiviral Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 44: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 45: Asia Pacific Respiratory Antiviral Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 46: Asia Pacific Respiratory Antiviral Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 47: Asia Pacific Respiratory Antiviral Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030

Figure 48: Asia Pacific Respiratory Antiviral Treatment Market Attractiveness Analysis, by Drug Class, 2020–2030

Figure 49: Asia Pacific Respiratory Antiviral Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030

Figure 50: Asia Pacific Respiratory Antiviral Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030

Figure 51: Asia Pacific Respiratory Antiviral Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 52: Asia Pacific Respiratory Antiviral Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 53: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 54: Latin America Respiratory Antiviral Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 55: Latin America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 56: Latin America Respiratory Antiviral Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030

Figure 57: Latin America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Drug Class, 2020–2030

Figure 58: Latin America Respiratory Antiviral Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030

Figure 59: Latin America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030

Figure 60: Latin America Respiratory Antiviral Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 61: Latin America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 62: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 63: Middle East & Africa Respiratory Antiviral Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 64: Middle East & Africa Respiratory Antiviral Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 65: Middle East & Africa Respiratory Antiviral Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030

Figure 66: Middle East & Africa Respiratory Antiviral Treatment Market Attractiveness Analysis, by Drug Class, 2020–2030

Figure 67: Middle East & Africa Respiratory Antiviral Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030

Figure 68: Middle East & Africa Respiratory Antiviral Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030

Figure 69: Middle East & Africa Respiratory Antiviral Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 70: Middle East & Africa Respiratory Antiviral Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界の呼吸器抗ウィルス治療市場2020年ー2030年:薬剤分類別(ヌクレオシド類似体、ノイラミニダーゼ阻害剤、イオンチャネル遮断薬、融合タンパク質阻害剤)、疾患別、流通チャネル別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆